Inertia on hypoglycemia: Highlight from a Taiwan subgroup analysis of Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study

Diabetes Research and Clinical Practice

Volumn 98, Issue 1, 2012, Pages 61-67

  Wang, Chih Yuan ^a   Lin, Ching Ling ^b   Huang, Tien Shiang ^a   Chien, Ming Nan ^c   Hsieh, Sheng Hwu ^d   Huang, Yu Yao ^e   Shih, Kuang Chung ^f   Tu, Shih Te ^g   Chang, Chwen Tzuei ^h   Chien Ning, Huang ⁱ   Chou, Chien Wen ^j   Wu, Ta Jen ^k   Liu, Rue Tsuan ^e   Lam, Hing Chung ^l   Kwok, Ching Fai ^m   Fu, Chen Chung ⁿ   Sheu, Wayne H H ^o  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^g Department of Internal Medicine   (Taiwan)

^h CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^j Chi Mei General Hospital   (Taiwan)

^k NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^l KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^m NATIONAL YANG MING UNIVERSITY   (Taiwan)

ⁿ BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^o TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

more..

Author keywords

Diabetes mellitus; EQ 5D; Hypoglycemia; Inertia; RECAP DM

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; ASIA; CLINICAL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; GLYCEMIC CONTROL; HEALTH CARE QUALITY; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT SATISFACTION; POPULATION RESEARCH; PRACTICE GUIDELINE; QUALITY OF LIFE; SCORING SYSTEM; SOCIOECONOMICS; SYMPTOMATOLOGY; TAIWAN;

ASIA; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; MALE; MIDDLE AGED; PACIFIC ISLANDS; PATIENT COMPLIANCE; QUALITY OF HEALTH CARE; RISK ASSESSMENT; TAIWAN; TREATMENT OUTCOME;

EID: 84867397921     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.05.017     Document Type: Article

References (33)

1. Bhattarai M.D. Three patterns of rising type 2 diabetes prevalence in the world: need to widen the concept of prevention in individuals into control in the community. JNMA J Nepal Med Assoc 2009, 48(174):173-179.
2. Chang C.H., Shau W.Y., Jiang Y.D., Li H.Y., Chang T.J., Sheu W.H., et al. Type 2 diabetes prevalence and incidence among adults in Taiwan during 1999-2004: a national health insurance data set study. Diabet Med 2010, 27(6):636-643.
3. Wong K.C., Wang Z. Prevalence of type 2 diabetes mellitus of Chinese populations in Mainland China, Hong Kong, and Taiwan. Diabetes Res Clin Pract 2006, 73(2):126-134.
4. American Diabetes, Association Standards of medical care in diabetes-2006. Diabetes Care 2006, 29(Suppl. 1):S4-S42.
5. Asia Pacific Type 2 Diabetes Policy Group. Type 2 diabetes practical targets and treatments. 4th edition, ; 2005 [accessed 10.08.11]. http://www.psad-easd.eu/.
6. Chuang L.M., Soegondo S., Soewondo P., Young-Seol K., Mohamed M., Dalisay E., et al. Comparisons of the outcomes on control, type of management and complications status in early onset and late onset type 2 diabetes in Asia. Diabetes Res Clin Pract 2006, 71(2):146-155.
7. Liu Z., Fu C., Wang W., Xu B. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes 2010, 8:62.
8. Chan S.P., Ji L.N., Nitiyanant W., Baik S.H., Sheu W.H. Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific-Real-Life Effectiveness and Care Patterns of Diabetes Management: the RECAP-DM study. Diabetes Res Clin Pract 2010, 89(2):e30-e32.
9. Vexiau P., Mavros P., Krishnarajah G., Lyu R., Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008, 10(Suppl. 1):16-24.
10. Zoungas S., Patel A., Chalmers J., de Galan B.E., Li Q., Billot L., et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363(15):1410-1418.
11. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
12. Desouza C., Salazar H., Cheong B., Murgo J., Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003, 26(5):1485-1489.
13. Anderson R.T., Narayan K.M., Feeney P., Goff D., Ali M.K., Simmons D.L., et al. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care 2011, 34(4):807-812.
14. Riddle M.C., Ambrosius W.T., Brillon D.J., Buse J.B., Byington R.P., Cohen R.M., et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010, 33(5):983-990.
15. Alvarez-Guisasola F., Yin D.D., Nocea G., Qiu Y., Mavros P. Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study. Health Qual Life Outcomes 2010, 8:86.
16. Lundkvist J., Berne C., Bolinder B., Jönsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005, 6(3):197-202.
17. Marrett E., Radican L., Davies M.J., Zhang Q. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes 2011, 4:251.
18. Hsiao Y.C., Chien M.N. Severe hypoglycemia in type 2 diabetes: a hospital-based retrospective study. J Intern Med Taiwan 2006, 17:73-77.
19. Kuritzky L. Managing type 2 diabetes in the primary care setting: beyond glucocentricity. Am J Med Sci 2010, 340(2):133-143.
20. Cryer P.E., Davis S.N., Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003, 26(6):1902-1912.
21. Chico A., Vidal-Ríos P., Subirà M., Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003, 26(4):1153-1157.
22. Pedersen-Bjergaard U., Pramming S., Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev 2003, 19(3):232-240.
23. Wu H., Xu M.J., Zou D.J., Han Q.J., Hu X. Intensive glycemic control and macrovascular events in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Chin Med J (Engl) 2010, 123(20):2908-2913.
24. Ismail-Beigi F., Moghissi E., Tiktin M., Hirsch I.B., Inzucchi S.E., Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011, 154(8):554-559.
25. Alvarez Guisasola F., Mavros P., Nocea G., Alemao E., Alexander C.M., Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 2008, 10(Suppl. 1):8-15.
26. McPherson M.L., Smith S.W., Powers A., Zuckerman I.H. Association between diabetes patients' knowledge about medications and their blood glucose control. Res Social Adm Pharm 2008, 4(1):37-45.
27. Chiu Y.W., Chang J.M., Lin L.I., Chang P.Y., Lo W.C., Wu L.C., et al. Adherence to a diabetic care plan provides better glycemic control in ambulatory patients with type 2 diabetes. Kaohsiung J Med Sci 2009, 25(4):184-192.
28. Graham R. Self-monitoring of blood glucose (SMBG): considerations for intensive diabetes management. Pharm Ther (Suppl.) 2005, 30(12).
29. Ahrén B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes 2010, 3:31-41.
30. Ahrén B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004, 89(5):2078-2084.
31. Goldstein B.J., Feinglos M.N., Lunceford J.K., Johnson J., Williams-Herman D.E. Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30(8):1979-1987.
32. Mohan V., Yang W., Son H.Y., Xu L., Noble L., Langdon R.B., et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009, 83(1):106-116.
33. Schwarz B., Gouveia M., Chen J., Nocea G., Jameson K., Cook J., et al. Cost-effectiveness of sitagliptin based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008, 10(Suppl. 1):43-55.